Carotid stent reimbursement hurdles?
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis (Precise) could run into difficulties overturning CMS' national non-coverage decision for carotid stents, according to Coverage & Analysis Group Director Steve Phurrough. The CMS official observed that the FDA panel reviewing the product April 21 "was not very positive at all," and that the 6-5 vote in favor of approval is "not a ringing endorsement." (1"The Gray Sheet" April 26, 2004, p. 3) Phurrough's comments arose during the Schwab Soundview Capital Markets meeting in Washington, D.C. May 6...